BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lyu Q, Lin A, Cao M, Xu A, Luo P, Zhang J. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition. Cancer Control 2020;27:1073274820976665. [PMID: 33356494 DOI: 10.1177/1073274820976665] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen C, Liu J, Chen Y, Lin A, Mou W, Zhu L, Yang T, Cheng Q, Zhang J, Luo P. Application of ATAC-seq in tumor-specific T cell exhaustion. Cancer Gene Ther 2023;30:1-10. [PMID: 35794339 DOI: 10.1038/s41417-022-00495-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang G, Miao C, Mo L, Kahlert UD, Wu J, Ou M, Huang R, Feng R, Pang W, Shi W. MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients. Front Immunol 2022;13:1048503. [PMID: 36582246 DOI: 10.3389/fimmu.2022.1048503] [Reference Citation Analysis]
3 Liang Chen, Xiaobo Huang, Liulin Xiong, Weinan Chen, Lizhe An, Huanrui Wang, Yang Hong, Huina Wang. Analysis of prognostic oncogene filaggrin (FLG) wild-type subtype and its implications for immune checkpoint blockade therapy in bladder urothelial carcinoma. Transl Androl Urol 2022;11. [PMID: 36386263 DOI: 10.21037/tau-22-573] [Reference Citation Analysis]
4 Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther 2022;7:331. [PMID: 36123348 DOI: 10.1038/s41392-022-01136-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Jiang S, Geng S, Luo X, Zhang C, Yu Y, Cheng M, Zhang S, Shi N, Dong M. Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors. Front Immunol 2022;13:995785. [DOI: 10.3389/fimmu.2022.995785] [Reference Citation Analysis]
6 Liu S, Geng S, Shi N, Zhang L, Xue W, Li Y, Jiang K. Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation. Front Pharmacol 2022;13:878540. [PMID: 35401171 DOI: 10.3389/fphar.2022.878540] [Reference Citation Analysis]
7 Lin A, Qi C, Wei T, Li M, Cheng Q, Liu Z, Luo P, Zhang J. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer. Brief Bioinform 2022:bbac129. [PMID: 35395670 DOI: 10.1093/bib/bbac129] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
8 Zou XL, Li XB, Ke H, Zhang GY, Tang Q, Yuan J, Zhou CJ, Zhang JL, Zhang R, Chen WY. Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer. Front Immunol 2021;12:689076. [PMID: 34992591 DOI: 10.3389/fimmu.2021.689076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
9 Yi R, Hong S, Zhang Y, Lin A, Ying H, Zou W, Wang Q, Wei T, Cheng Q, Zhu W, Luo P, Zhang J. MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer. Front Cell Dev Biol 2022;10:757137. [DOI: 10.3389/fcell.2022.757137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Lin X, Deng J, Deng H, Yang Y, Sun N, Zhou M, Qin Y, Xie X, Li S, Zhong N, Song Y, Zhou C. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis. Front Immunol 2021;12:818492. [PMID: 35095920 DOI: 10.3389/fimmu.2021.818492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Li J, Pan H, Pi X, Xiong Y. Model Construction and Identification of Genome Instability-Associated LncRNA Signature Markers in Bladder Cancer. JBM 2022;10:46-63. [DOI: 10.4236/jbm.2022.101006] [Reference Citation Analysis]
12 Startsev VY, Balashov AE, Merzlyakov AS, Vorobiov SL, Kozorezova ES. Molecular determinants of recurrences of the human urothelial tumor. Onkourologiâ 2021;17:130-139. [DOI: 10.17650/1726-9776-2021-17-3-130-139] [Reference Citation Analysis]
13 Ma B, Jiang H, Luo Y, Liao T, Xu W, Wang X, Dong C, Ji Q, Wang Y. Tumor-Infiltrating Immune-Related Long Non-Coding RNAs Indicate Prognoses and Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma. Front Immunol 2021;12:692079. [PMID: 34737735 DOI: 10.3389/fimmu.2021.692079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Sun Y, Yang Q, Shen J, Wei T, Shen W, Zhang N, Luo P, Zhang J. The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Front Cell Dev Biol 2021;9:745859. [PMID: 34660603 DOI: 10.3389/fcell.2021.745859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 He Y, Wu Y, Liu Z, Li B, Jiang N, Xu P, Xu A. Identification of Signature Genes Associated With Invasiveness and the Construction of a Prognostic Model That Predicts the Overall Survival of Bladder Cancer. Front Genet 2021;12:694777. [PMID: 34589112 DOI: 10.3389/fgene.2021.694777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Lin A, Wei T, Liang J, Qi C, Li M, Luo P, Zhang J. CAMOIP: A Web Server for Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer.. [DOI: 10.1101/2021.09.10.459722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Zhang Q, Liu Y, Chen P, Shi X, Liu Y, Shi L, Cong P, Mao S, Tong C, Du C, Hou M. Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer. Bioengineered 2021;12:4946-61. [PMID: 34365894 DOI: 10.1080/21655979.2021.1962485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]